Summit Therapeutics (SMMT) to Release Quarterly Earnings on Tuesday

Key Points

• Summit Therapeutics is projected to release its Q2 2025 earnings on August 5th, with analysts expecting a loss of ($0.10) per share.
• The company's last quarterly earnings showed a smaller loss of ($0.09) per share, beating expectations by $0.01.
• Summit Therapeutics has a market capitalization of $20.39 billion, with a consensus price target of $34.67 among analysts rating the stock as a "Moderate Buy."

Summit Therapeutics (NASDAQ:SMMT - Get Free Report) is expected to release its Q2 2025 earnings data before the market opens on Tuesday, August 5th. Analysts expect Summit Therapeutics to post earnings of ($0.10) per share for the quarter.

Summit Therapeutics (NASDAQ:SMMT - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. On average, analysts expect Summit Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Summit Therapeutics Stock Down 0.3%

NASDAQ:SMMT traded down $0.08 during trading hours on Wednesday, hitting $26.66. 3,366,357 shares of the company's stock traded hands, compared to its average volume of 3,243,513. The firm has a market cap of $19.80 billion, a P/E ratio of -78.41 and a beta of -1.01. Summit Therapeutics has a 52 week low of $8.88 and a 52 week high of $36.91. The business's fifty day simple moving average is $23.31 and its two-hundred day simple moving average is $22.20.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on SMMT. HC Wainwright reissued a "buy" rating and set a $44.00 price objective on shares of Summit Therapeutics in a research note on Tuesday, July 1st. Wall Street Zen raised Summit Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, June 29th. The Goldman Sachs Group lifted their price target on Summit Therapeutics from $37.00 to $41.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Jefferies Financial Group set a $44.00 price target on Summit Therapeutics and gave the stock a "buy" rating in a research note on Friday, April 25th. Finally, Leerink Partners began coverage on Summit Therapeutics in a research note on Wednesday, June 11th. They set an "underperform" rating and a $12.00 price target for the company. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Summit Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $34.67.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Summit Therapeutics stock. AQR Capital Management LLC boosted its position in Summit Therapeutics PLC (NASDAQ:SMMT - Free Report) by 5.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 65,623 shares of the company's stock after purchasing an additional 3,134 shares during the quarter. AQR Capital Management LLC's holdings in Summit Therapeutics were worth $1,266,000 at the end of the most recent quarter. 4.61% of the stock is owned by institutional investors and hedge funds.

About Summit Therapeutics

Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.